A Study on Relationship Between Resected Normal Liver Parenchymal Volume（RNLV）and Post-Hepatectomy Liver Failure (PHLF)

NCT06366048 · tracked via the Priya Life Science China tracker

Sponsor

National Natural Science Foundation of China

Phase

Observational

Started

2022-12-01

Last updated

2026-04-14

Condition(s) studied

Liver Failure

Investigational drug(s) / intervention(s)

the different definitions of PHLF according to 50-50 criteria and ISGLS criteria

the different definitions of PHLF according to 50-50 criteria and ISGLS criteria: Our study respectively defined the PHLF according to the 50-50 criteria and the ISGLS criteria in literature review.

Study summary

The post-hepatotectomy liver failure (PHLF) is still the most worrisome complication of hepatic resection. Surgeons have always been making efforts to preoperatively predict PHLF using kinds of techniques, scoring systems, and variables. The investigators of this study tried to create an individual predictive model based on the variable, resected normal parenchymal volume (RNLV), then assessing the performance and value of the model in clinical practice.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion criteria: * selective hepatectomies; * histologically confirmed as HCC and ICC * complete and accessible data Exclusion criteria: * any history of Associated Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) * any history of portal vein embolism (PVE) * any history of tumor rupture * emergency surgery * pathologically diagnosed with neither HCC nor ICC * concomitant resection of gastrointestinal organs, spleenectomy or other organs

Primary outcome measure(s)

Probability of PHLF was predicted with our individual model based on RNLV. — postoperative day 1 to day 30.
In our center, an increase international normalized ratio greater than 1.15 and concomitant hyperbilirubinemia more than 23μmol/L on or after postoperative day 5 would be defined as PHLF, according to the International Study Group of Liver Surgery.

Trial sites (3)

Facility	City	Region	Status
Mengchao Hepatobiliary Hospital of Fujian Medical University	Fujian	Shanghai Municipality	Recruiting
The Third Affiliated Hospital of Naval Medical University	Shanhai	Shanghai Municipality	Recruiting
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen, Mengchao Hepatobiliary Hospital of Fujian Medical University	Shenzhencun	Shanghai Municipality	Recruiting

More National Natural Science Foundation of China trials in China

Study on the Relationship Between Indoor Environment, Use of Personal Disinfection Products, and Human Health Active, not recruiting

Other trials for the same condition

Registry Study for Optimal Management of Liver Failure in the Chinese Population Recruiting

The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure Recruiting

Safety and Effectiveness of Mesenchymal Stem Cells in Blood Purification for the Treatment of Liver Failure Recruiting

Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC Recruiting

CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06366048 on ClinicalTrials.gov ↗ ← All trials in China